Reductions in Myocardial Interstitial Fibrosis are Dissociated From LV Chamber Stiffness in Swine with Repetitive Pressure Overload

<b>Background:</b> Cardiosphere-derived cells (CDCs) and the non-steroidal aldosterone antagonist finerenone can each reduce myocardial fibrosis and have emerged as potential therapeutics for HFpEF. While these interventions can improve diastolic properties, their direct effects on LV chamber stiffness have not been established. Accordingly, we examined their effect in swine with increased LV chamber stiffness and fibrosis from repetitive pressure overload (RPO). <b>Methods:</b> Swine (n=19) were subjected to daily (1-hour) episodes of RPO for 2-weeks using phenylephrine to transiently elevate LVEDP to ~30mmHg. After 2-weeks, RPO was discontinued and animals received intracoronary saline (n=6), allogeneic CDCs (30x106, n=7) or oral finerenone (20mg/day; n=6) and were followed for 4-weeks. LV end-diastolic pressure and end-diastolic volume index were measured at normal and elevated preload to assess LV chamber stiffness (ΔLVEDP/ΔLVEDVi) and post-mortem picrosirius red staining was performed to quantify interstitial fibrosis. <b>Results:</b> Four-weeks after cessation of RPO, saline-treated swine demonstrated sustained increases in LV chamber stiffness (1.7±0.3mmHg/mL/m<sup>2</sup> vs. 0.6±0.1mmHg/mL/m<sup>2</sup> in controls, p<0.01). This was associated with increased fibrosis (8.5±0.7% vs. 6.7±0.4% in controls, p<0.05) that decreased after treatment with CDCs (6.1±0.5%, p<0.05) and finerenone (5.4±0.6%, p<0.05). Despite these anti-fibrotic effects, LV chamber stiffness remained elevated after both agents (CDCs: 1.9±0.4mmHg/mL/m<sup>2</sup>; finerenone: 1.4±0.3mmHg/mL/m<sup>2</sup>, both p<0.05 vs. normal controls). <b>Conclusion:</b> Although both CDCs and finerenone reduced fibrosis, these changes were not associated with reductions in LV chamber stiffness. Additional mechanisms likely underlie increased LV chamber stiffness in this model, which may have relevance to the therapeutic impact of these interventions on diastolic function in HFpEF.

Authors

Institutions

Publication Details

Journal
American Journal of Physiology-Heart and Circulatory Physiology
Published
2026-03-12
DOI
https://doi.org/10.1152/ajpheart.00082.2026
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reductions in Myocardial Interstitial Fibrosis are Dissociated From LV Chamber Stiffness in Swine with Repetitive Pressure Overload

Brian R. Weil, Alexandra K. Gilligan, John M. Canty, Emily Hudson
American Journal of Physiology-Heart and Circulatory Physiology
Cardiac Fibrosis and Remodeling
article

Reductions in Myocardial Interstitial Fibrosis are Dissociated From LV Chamber Stiffness in Swine with Repetitive Pressure Overload

Brian R. Weil, Alexandra K. Gilligan, John M. Canty, Emily Hudson
article en

Abstract

<b>Background:</b> Cardiosphere-derived cells (CDCs) and the non-steroidal aldosterone antagonist finerenone can each reduce myocardial fibrosis and have emerged as potential therapeutics for HFpEF. While these interventions can improve diastolic properties, their direct effects on LV chamber stiffness have not been established. Accordingly, we examined their effect in swine with increased LV chamber stiffness and fibrosis from repetitive pressure overload (RPO). <b>Methods:</b> Swine (n=19) were subjected to daily (1-hour) episodes of RPO for 2-weeks using phenylephrine to transiently elevate LVEDP to ~30mmHg. After 2-weeks, RPO was discontinued and animals received intracoronary saline (n=6), allogeneic CDCs (30x106, n=7) or oral finerenone (20mg/day; n=6) and were followed for 4-weeks. LV end-diastolic pressure and end-diastolic volume index were measured at normal and elevated preload to assess LV chamber stiffness (ΔLVEDP/ΔLVEDVi) and post-mortem picrosirius red staining was performed to quantify interstitial fibrosis. <b>Results:</b> Four-weeks after cessation of RPO, saline-treated swine demonstrated sustained increases in LV chamber stiffness (1.7±0.3mmHg/mL/m<sup>2</sup> vs. 0.6±0.1mmHg/mL/m<sup>2</sup> in controls, p<0.01). This was associated with increased fibrosis (8.5±0.7% vs. 6.7±0.4% in controls, p<0.05) that decreased after treatment with CDCs (6.1±0.5%, p<0.05) and finerenone (5.4±0.6%, p<0.05). Despite these anti-fibrotic effects, LV chamber stiffness remained elevated after both agents (CDCs: 1.9±0.4mmHg/mL/m<sup>2</sup>; finerenone: 1.4±0.3mmHg/mL/m<sup>2</sup>, both p<0.05 vs. normal controls). <b>Conclusion:</b> Although both CDCs and finerenone reduced fibrosis, these changes were not associated with reductions in LV chamber stiffness. Additional mechanisms likely underlie increased LV chamber stiffness in this model, which may have relevance to the therapeutic impact of these interventions on diastolic function in HFpEF.

American Journal of Physiology-Heart and Circulatory Physiology
University at Buffalo, State University of New York (US)
Good health and well-being
Openalex Percentile: Top 33%
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.